# Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults

> **NCT06302374** · PHASE1,PHASE2 · COMPLETED · sponsor: **Genrix (Shanghai) Biopharmaceutical Co., Ltd.** · enrollment: 202 (actual)

## Conditions studied

- Tetanus

## Interventions

- **BIOLOGICAL:** GR2001
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** HTIG
- **BIOLOGICAL:** Tetanus Toxoid

## Key facts

- **NCT ID:** NCT06302374
- **Lead sponsor:** Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-04
- **Primary completion:** 2023-11-01
- **Final completion:** 2024-02-19
- **Target enrollment:** 202 (ACTUAL)
- **Last updated:** 2024-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06302374

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06302374, "Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06302374. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*